TWi Biotechnology, Inc.
10
0
1
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.0%
1 terminated/withdrawn out of 10 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
38%
3 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Role: lead
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
Role: lead
A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Role: lead
Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy
Role: lead
Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study
Role: lead
A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy
Role: lead
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
Role: lead
A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients
Role: lead
A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Role: lead
Study of AC-201 in Patients With Type 2 Diabetes Mellitus
Role: lead
All 10 trials loaded